Detectable ctDNA Before Adjuvant Therapy for Melanoma May Predict Recurrence

(MedPage Today) -- Droplet digital PCR measurements of circulating tumor (ct)DNA to assess minimal residual disease before the initiation of adjuvant therapy and during follow-up for patients with resected stage III melanoma may accurately identify...